Pharma Mar SAU
Research Pharma Mar SAU (PMRA) on Bullrun: valuation model: 10.7% undervalued, market cap EUR 1.20B, P/E 14.9, dividend yield 1.2%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPMRA
- ExchangeF
- CountrySpain
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Valuation signal10.7% undervalued
- Market capEUR 1.20B
- P/E14.9
- Dividend yield1.2%
- Financial periodFY2024
- RevenueEUR 174.86M
- Revenue growth10.6%
- Net incomeEUR 26.13M
- Free cash flow-EUR 8.99M
- Gross margin95.3%
Valuation Snapshot
Bullrun's latest valuation model marks Pharma Mar SAU as 10.7% undervalued; latest market cap is EUR 1.20B; P/E is 14.9; dividend yield is 1.2%.
About Pharma Mar SAU
Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. It operates through Oncology and RNA Interference segments. The company offers Yondelis, a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata that treats soft tissue sarcoma and ovarian cancer;
Frequently asked questions
Is Pharma Mar SAU overvalued or undervalued?
Bullrun's valuation model currently marks Pharma Mar SAU as 10.7% undervalued.
What is Pharma Mar SAU's market cap?
Pharma Mar SAU's market capitalization is EUR 1.20B.
What is Pharma Mar SAU's P/E ratio?
Pharma Mar SAU's price-to-earnings (P/E) ratio is 14.9.
Does Pharma Mar SAU pay a dividend?
Pharma Mar SAU has a dividend yield of 1.2%.
What does Pharma Mar SAU do?
Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally.